Nykode Therapeutics (NYKD) Q3 2024 earnings summary

Executive summary

• Strategic refocus aims to reduce annual costs to approximately $20 million, extend cash runway into 2030, and transition to a leaner, research-driven organization.

• Staff reduction of about 50% aligns with new priorities, focusing on advancing the Vaccibody platform and early-stage partnerships.

• Regained full control of VB10.NEO after Genentech's exit, with new U.S. patent granted and ongoing search for new partners.

• Strong cash position of $124.6 million at quarter end supports the extended runway and strategic initiatives.

• Clinical progress continues for VB10.16 and VB10.NEO, with further trials contingent on partnerships.

Financial highlights

• Q3 2024 revenue and other income totaled $0.7 million, mainly from R&D activities and government grants.

• Q3 2024 net loss was $9.7 million, a slight improvement from $10.2 million in Q3 2023.

• Operating expenses for Q3 2024 were $15.6 million, down from $17.1 million in Q3 2023.

• Cash and cash equivalents at September 30, 2024, were $124.6 million.

• Net cash outflow from operations for Q3 2024 was $12.7 million.

Outlook and guidance

• Cost base targeted at $20 million per annum, with cash runway extended into 2030.

• Further development of VB10.16 and VB10.NEO depends on securing new partnerships.

• Focus on advancing inverse vaccine leadership for autoimmune diseases, allergies, and organ transplantation rejection.

• Continued innovation in cancer vaccines and pursuit of early partnerships for future assets.

• Updated strategy enables targeted investments in high-value initiatives and cost-efficient trials.